Skip to content
VuFind
    • English
    • Deutsch
    • Español
    • Français
    • Italiano
    • 日本語
    • Nederlands
    • Português
    • Português (Brasil)
    • 中文(简体)
    • 中文(繁體)
    • Türkçe
    • עברית
    • Gaeilge
    • Cymraeg
    • Ελληνικά
    • Català
    • Euskara
    • Русский
    • Čeština
    • Suomi
    • Svenska
    • polski
    • Dansk
    • slovenščina
    • اللغة العربية
    • বাংলা
    • Galego
    • Tiếng Việt
    • Hrvatski
    • हिंदी
    • Հայերէն
    • Українська
    • Sámegiella
    • Монгол
Advanced
  • Outcomes of systemic Janus kin...
  • Cite this
  • Text this
  • Email this
  • Print
  • Export Record
    • Export to RefWorks
    • Export to EndNoteWeb
    • Export to EndNote
  • Permanent link
Outcomes of systemic Janus kinase inhibitors following prior dupilumab use for atopic dermatitis: An evidence-based review

Outcomes of systemic Janus kinase inhibitors following prior dupilumab use for atopic dermatitis: An evidence-based review

Bibliographic Details
Main Authors: Siddhartha Sood, HBSc, Ahmed Bagit, BSc, Martin Heung, Khalad Maliyar, MD, Abrahim Abduelmula, MD, Muskaan Sachdeva, MD, Jorge R. Georgakopoulos, MD, Asfandyar Mufti, MD, Vimal H. Prajapati, MD, Jensen Yeung, MD
Format: Article
Language:English
Published: Elsevier 2024-09-01
Series:JAAD International
Subjects:
abrocitinib
atopic dermatitis
baricitinib
dupilumab
evidence-based
Janus kinase inhibitor
Online Access:http://www.sciencedirect.com/science/article/pii/S2666328724000658
  • Holdings
  • Description
  • Similar Items
  • Staff View

Internet

http://www.sciencedirect.com/science/article/pii/S2666328724000658

Similar Items

  • Weight gain secondary to the use of oral Janus kinase inhibitors: A systematic review and meta-analysis
    by: Grace Xiong, BHSc, et al.
    Published: (2025-04-01)
  • Janus Kinase Inhibitors for the Treatment of Atopic Dermatitis: Focus on Abrocitinib, Baricitinib, and Upadacitinib
    by: Miguel Nogueira, et al.
    Published: (2021-10-01)
  • Systematic Review on the Efficacy and Safety of Oral Janus Kinase Inhibitors for the Treatment of Atopic Dermatitis
    by: Michelle Le, et al.
    Published: (2021-09-01)
  • Comparison between dupilumab and oral Janus kinase inhibitors in the treatment of prurigo nodularis with or without atopic dermatitis in a tertiary care center in Singapore
    by: Yik Weng Yew, MBBS, MPH, PhD, et al.
    Published: (2023-12-01)
  • Management of vitiligo with topical janus tyrosine kinase inhibitor therapy: An evidence-based review
    by: Abrahim Abduelmula, BScN, et al.
    Published: (2022-12-01)

Search Options

  • Search History
  • Advanced Search

Find More

  • Browse the Catalog
  • Browse Alphabetically
  • Explore Channels
  • Course Reserves
  • New Items

Need Help?

  • Search Tips
  • Ask a Librarian
  • FAQs